Antidiabetic activity in Zucker diabetic fatty rat assessed as increase in total GLP-1 level at 0.05 to 10 mg/kg, po bid for 2 weeks measured on day 14 relative to vehicle-treated control
Antidiabetic activity in Zucker diabetic fatty rat assessed as increase in plasma insulin level at 0.05 to 10 mg/kg, po bid for 2 weeks measured on day 14 relative to vehicle-treated control
Antidiabetic activity in Zucker diabetic fatty rat assessed as reduction in non-fasted plasma glucose level at 0.05 to 10 mg/kg, po bid for 2 weeks measured on day 14 relative to vehicle-treated control
Antidiabetic activity in Zucker diabetic fatty rat assessed as reduction in blood HbA1c level at 0.05 to 10 mg/kg, po bid for 2 weeks measured on day 14 relative to vehicle-treated control
Antidiabetic activity in Zucker diabetic fatty rat assessed as increase in fecal bile acid excretion at 0.05 to 10 mg/kg, po bid for 2 weeks measured for 24 hrs post last dose relative to vehicle-treated control
Antidiabetic activity in portal vein cannulated lean Sprague-Dawley rat assessed as effect on portal vein GIP level at 10 mg/kg, po measured after 3 to 8 hrs relative to vehicle-treated control
Antidiabetic activity in portal vein cannulated lean Sprague-Dawley rat assessed as increase in portal vein PYY level at 10 mg/kg, po measured after 3 to 8 hrs
Antidiabetic activity in portal vein cannulated lean Sprague-Dawley rat assessed as increase in portal vein total GLP-1 level at 10 mg/kg, po measured after 3 to 8 hrs
In vivo inhibition of ASBT in portal vein cannulated lean Sprague-Dawley rat assessed as decrease in portal vein bile acid level at 10 mg/kg, po measured after 1 to 2 hrs relative to vehicle-treated control